면역측정(Immunoassay) 시장 : 2027년 까지의 세계 예측

출판 : MarketsandMarkets(마켓츠앤마켓츠)출판년월 : 2022년08월

면역측정(Immunoassay) 시장 : 제품(시약, 키트, 분석기), 기술(ELISA, 신속 검사, 웨스턴 블롯팅, ELISPOT), 시료(혈액, 타액), 용도(감염, 종양학), 최종 사용자(병원, 클리닉) – 2027년 까지의 세계 예측
Immunoassay Market by Product (Reagents & Kits, Analyzers), Technology (ELISA, Rapid Test, Western Blotting, ELISPOT), Specimen (Blood, Saliva), Application (Infectious Diseases, Oncology), End User (Hospitals & Clinics) – Global Forecasts to 2027

페이지수 417
도표수 415
구성 영문조사보고서
가격

리포트목차    주문/문의    납기/라이센스안내

Sample Request

The global immunoassay market is valued at an estimated USD 40.2 billion in 2022 and is projected to reach USD 49.6 billion by 2027, at a CAGR of 4.3% during the forecast period. Market growth is driven by factors such as the increasing incidence of chronic and infectious diseases, advancements in systems and technologies, growth in the biotechnology and biopharmaceutical industries, supportive government policies, increasing adoption of immunoassay-based POC testing and rapid testing, and increasing drug and alcohol abuse and stringent laws mandating drug and alcohol testing.
세계 면역측정 시장은 2022년에 402억 달러로 추산되며 예측 기간 동안 CAGR 4.3%로 2027년까지 496억 달러에 이를 것으로 예상됩니다. 시장 성장은 만성 및 전염병의 발병률 증가, 시스템 및 기술의 발전, 생명 공학 및 바이오 제약 산업의 성장, 지원 정부 정책, 면역 분석 기반 POC 테스트 및 신속한 테스트의 채택 증가, 약물 증가와 같은 요인에 의해 주도됩니다.
증가하는 약물 및 알코올 남용 및 약물 및 알코올 검사를 의무화하는 엄격한 법률.

면역측정(Immunoassay) 시장 : 제품(시약, 키트, 분석기), 기술(ELISA, 신속 검사, 웨스턴 블롯팅, ELISPOT), 시료(혈액, 타액), 용도(감염, 종양학), 최종 사용자(병원, 클리닉) - 2027년 까지의 세계 예측
“The reagents & kits to register the largest share of the immunoassay market, by product”
The global immunoassay market is segmented into reagents & kits and analyzers based on product. Market growth is largely driven by the large consumption of reagents & kits for various procedures along with the rising volume of immunoassay-based tests performed worldwide.
“Rapid Tests segment to grow at a considerable rate among technology during the forecast period”
The immunoassay market is segmented into ELISA, rapid tests, ELISpot, western blotting, radioimmunoassays, and other technologies. Rapid tests are used to test donated blood for the detection of HIV, HCV, HBV, and HCG antibodies. Rapid tests are preferred as a preferred method in POC diagnosis, particularly in emergency and primary care settings.

면역측정(Immunoassay) 시장 : 제품(시약, 키트, 분석기), 기술(ELISA, 신속 검사, 웨스턴 블롯팅, ELISPOT), 시료(혈액, 타액), 용도(감염, 종양학), 최종 사용자(병원, 클리닉) - 2027년 까지의 세계 예측
“The blood segment accounted to grow at the fastest rate, by specimen, in 2021”
Based on specimens, the immunoassay market is segmented into blood, saliva, urine, and other specimens. In 2021, blood specimens is anticipated to witness growth at the highest rate owing to increasing incidence of chronic and infectious diseases and rise in the rate of blood donations.
“Infectious diseases segment to register the highest growth rate among applications during the forecast period”
The global immunoassay market is segmented into infectious diseases, endocrinology, oncology, bone & mineral disorders, cardiology, blood screening, autoimmune disorders, allergy diagnostics, toxicology, newborn screening, and other applications. The application segment of infectious diseases is anticipated to grow that the highest CAGR during the forecast period, owing to the rise in the number of products being launched for its diagnosis.
“Among the end users, the hospitals & clinics segment anticipated to grow at a significant rate during the forecast period”
The rise in the prevalence of chronic and infectious diseases has led to significant growth of the hospitals & clinics end user segment. The segment is also consider to register highest growth rate during the forecast period.
“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”
The global immunoassay market is segmented into five regions – North America, Europe, the Asia Pacific, Middle East & Africa, and Latin America. The Asia Pacific region is expected to witness the highest growth in the immunoassay market during the forecast period. The high growth in this region can primarily be attributed to the increasing geriatric population, and high disease burden of chronic disorders along with developing healthcare infrastructure in Asian countries such as India and China.
The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 – 28%, Tier 2 – 41%, and Tier 3 – 31%
• By Designation: C-level – 30%, D-level – 34%, and Others – 36%
• By Region: North America – 38%, Europe – 27%, Asia Pacific – 18%, Middle East & Africa – 11%, and Latin America – 6%
Lists of Companies Profiled in the Report:

• Abbott Laboratories (US)
• F. Hoffmann-La Roche (Switzerland)
• Siemens Healthineers (Germany)
• Thermo Fisher Scientific (US)
• Danaher Corporation (US)
• PerkinElmer (US)
• Becton, Dickinson and Company (US)
• DiaSorin S.p.A. (Italy)
• Bio- Rad Laboratories (US)
• Quidel Corporation (US)
• Ortho Clinical Diagnostics Holdings (US)
• bioMérieux (France)
• QIAGEN (Netherlands)
• Sysmex Corporation (Japan)
• Agilent Technologies (US)
• Mindray Medical International Company (China)
• Merck KGaA (Germany)
• Meridian Bioscience (US)
• Bio-Techne (US)
• Cellabs (Australia)
• Abnova Corporation (Taiwan)
• J. Mitra & Co. Pvt. Ltd. (India)
• Tosoh Corporation (Japan)
• Cell Sciences (US)
• Enzo Biochem (US)
• Creative Diagnostics (US)
• Boster Biological Technology (US)
• Elabscience (US)
• WAK-Chemie Medical (Germany)
• Sera Care (US)
• Epitope Diagnostics (US)
• Kamiya Biomedical Company (US)
• Gyros Protein Technologies (Sweden)
• Trivitron Healthcare (India)
• InBios International (US).

면역측정(Immunoassay) 시장 : 제품(시약, 키트, 분석기), 기술(ELISA, 신속 검사, 웨스턴 블롯팅, ELISPOT), 시료(혈액, 타액), 용도(감염, 종양학), 최종 사용자(병원, 클리닉) - 2027년 까지의 세계 예측

Research Coverage:
This report provides a detailed picture of the global immunoassay market. It aims at estimating the size and future growth potential of the market across different segments, such as product, technology, specimen, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunoassay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.


목차

TABLE OF CONTENTS

1  INTRODUCTION (Page No. – 44)
1.1  STUDY OBJECTIVES
1.2  MARKET DEFINITION
1.2.1  INCLUSIONS & EXCLUSIONS
1.3  MARKET SCOPE
FIGURE  1 IMMUNOASSAY MARKET
1.3.1  YEARS CONSIDERED
1.4  CURRENCY CONSIDERED
1.5  STAKEHOLDERS
1.6  SUMMARY OF CHANGES

2  RESEARCH METHODOLOGY (Page No. – 48)
2.1  RESEARCH DATA
FIGURE  2  RESEARCH DESIGN
2.1.1  SECONDARY DATA
2.1.1.1  SECONDARY SOURCES
2.1.2  PRIMARY DATA
2.1.2.1  KEY DATA FROM PRIMARY SOURCES
2.1.2.2  KEY INDUSTRY INSIGHTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2  MARKET SIZE ESTIMATION
2.2.1  BOTTOM-UP APPROACH
FIGURE 5  MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 6  MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 7  CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3  MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4  MARKET SHARE ANALYSIS
2.5  STUDY ASSUMPTIONS
2.6  RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT: IMMUNOASSAY MARKET
2.7  LIMITATIONS
2.7.1  METHODOLOGY-RELATED LIMITATIONS
2.7.2  SCOPE-RELATED LIMITATIONS
2.8  GROWTH RATE ASSUMPTIONS

3  EXECUTIVE SUMMARY (Page No. – 59)
FIGURE 9  IMMUNOASSAY MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION)
FIGURE 10  IMMUNOASSAY MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD BILLION)
FIGURE 11  IMMUNOASSAY MARKET, BY SPECIMEN, 2022 VS. 2027 (USD BILLION)
FIGURE 12  IMMUNOASSAY MARKET, BY APPLICATION, 2022 VS. 2027 (USD BILLION)
FIGURE 13  IMMUNOASSAY MARKET, BY END USER, 2022 VS. 2027 (USD BILLION)
FIGURE 14  GEOGRAPHICAL SNAPSHOT OF IMMUNOASSAY MARKET

4  PREMIUM INSIGHTS (Page No. – 65)
4.1  IMMUNOASSAY MARKET OVERVIEW
FIGURE 15  RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS—KEY DRIVERS OF MARKET GROWTH
4.2  NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT & COUNTRY (2021)
FIGURE 16 REAGENTS & KITS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021
4.3  IMMUNOASSAY MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 17  CHINA & INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD
4.4  IMMUNOASSAY MARKET: GEOGRAPHIC MIX
FIGURE 18  APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5  IMMUNOASSAY MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 19  DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5  MARKET OVERVIEW (Page No. – 70)
5.1  INTRODUCTION
5.2  MARKET DYNAMICS
FIGURE 20 IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1  DRIVERS
5.2.1.1  INCREASING INCIDENCE OF CHRONIC AND INFECTIOUS DISEASES AND GROWING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS
FIGURE 21  INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
TABLE 2  GLOBAL INCIDENCE OF INFECTIOUS DISEASES
5.2.1.1.1  INCREASING USE OF IMMUNOASSAYS IN ONCOLOGY
TABLE 3 GLOBAL INCIDENCE OF TOP CANCERS IN MEN, 2020
TABLE 4 GLOBAL INCIDENCE OF TOP CANCERS IN WOMEN, 2020
5.2.1.1.2 IMMUNOASSAYS FOR COVID-19 AND OTHER VIRAL DIAGNOSTICS
5.2.1.1.3 IMMUNOASSAYS IN DRUG DETECTION AND OTHER DIAGNOSTIC APPLICATIONS
TABLE 5  DETECTION OF DRUGS BY URINE TESTING
5.2.1.1.4  GROWING GERIATRIC POPULATION
FIGURE 22  GLOBAL AGING POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
5.2.1.2  ADVANCEMENTS IN SYSTEMS AND TECHNOLOGIES
5.2.1.3  GROWTH IN BIOTECHNOLOGY AND BIOPHARMACEUTICAL INDUSTRIES
5.2.1.4  INCREASING ADOPTION OF IMMUNOASSAY-BASED POC TESTING AND RAPID TESTING
TABLE 6  RECENT WAIVERS OF MARKET PRODUCTS
5.2.1.5  SUPPORTIVE GOVERNMENT POLICIES
5.2.1.6  INCREASING DRUG AND ALCOHOL ABUSE AND STRINGENT LAWS MANDATING DRUG AND ALCOHOL TESTING
5.2.2  RESTRAINTS
5.2.2.1 STRINGENT REQUIREMENTS FOR APPROVAL OF IMMUNOASSAY INSTRUMENTS AND CONSUMABLES
5.2.2.2 TECHNICAL HURDLES OF IMMUNOASSAY KITS
5.2.3  OPPORTUNITIES
5.2.3.1  GROWTH OPPORTUNITIES IN EMERGING ECONOMIES
5.2.3.2  IMPORTANCE OF COMPANION DIAGNOSTICS
TABLE 7  COMPANION DIAGNOSTIC ASSAYS APPROVED AND LAUNCHED
5.2.3.3  DEVELOPMENT OF CONDITION-SPECIFIC BIOMARKERS AND TESTS
TABLE 8  NEW TESTS LAUNCHED BY KEY PLAYERS
5.2.3.4  INTEGRATION OF MICROFLUIDICS IN IMMUNOASSAYS
TABLE 9 LAB-ON-A-CHIP IMMUNOASSAYS/DEVICES/SYSTEMS OFFERED BY PLAYERS
5.2.3.5  IMPROVING IMMUNOASSAY DIAGNOSTIC TECHNOLOGIES
5.2.4  CHALLENGES
5.2.4.1  DESIGN CHALLENGES, COMPLEXITIES, AND QUALITY OF ANTIBODIES
5.2.4.2  DEARTH OF SKILLED PROFESSIONALS
5.2.4.3  UNFAVORABLE REIMBURSEMENT SCENARIO
5.2.4.4  FINANCIAL HURDLES FACED BY PHYSICIANS
5.3  REGULATORY OVERVIEW
5.3.1  US
TABLE 10  US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
FIGURE 23  US: REGULATORY PROCESS FOR IVD DEVICES
5.3.2  CANADA
FIGURE 24  CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA
5.3.3  EUROPE
TABLE 11 EUROPE: CLASSIFICATION OF IVD DEVICES
5.3.4  JAPAN
5.3.4.1  JAPAN: REGULATORY PROCESS FOR IVD DEVICES
TABLE 12  JAPAN: CLASSIFICATION OF IVD REAGENTS IN JAPAN
TABLE 13  JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.5  CHINA
TABLE 14 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.6  INDIA
5.3.6.1  INDIA: REGULATORY PROCESS FOR IVD DEVICES
5.3.7  INDONESIA
TABLE 15  INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
5.3.8   RUSSIA
TABLE  16 RUSSIA: CLASSIFICATION OF IVD DEVICES
5.3.9   SAUDI ARABIA
TABLE 17  SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.10 MEXICO
5.3.10.1  MEXICO: REGULATORY PROCESS FOR IVD DEVICES
TABLE 18 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.11  BRAZIL
5.3.11.1  BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
5.3.12  SOUTH KOREA
TABLE 19  SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
5.3.13  MIDDLE EAST
5.3.14  AFRICA
5.4  TECHNOLOGY ANALYSIS
TABLE 20  CONVENTIONAL IMMUNOASSAY METHODS AND TECHNIQUES
TABLE 21  RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN IMMUNOASSAY MARKET
5.5  TRADE ANALYSIS
5.5.1  TRADE ANALYSIS FOR IMMUNOASSAYS
TABLE 22 IMPORT DATA FOR HS CODE 902750, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 23 EXPORT DATA FOR HS CODE 902750, BY COUNTRY, 2016–2020 (USD MILLION)
5.6  PATENT ANALYSIS
5.7  VALUE CHAIN ANALYSIS
FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.8  SUPPLY CHAIN ANALYSIS
FIGURE 26 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.9  ECOSYSTEM ANALYSIS OF IMMUNOASSAY MARKET
FIGURE 27 ECOSYSTEM ANALYSIS OF IMMUNOASSAY MARKET
5.9.1  ROLE IN ECOSYSTEM
5.9.2  KEY PLAYERS OPERATING IN IMMUNOASSAY MARKET
5.10  PORTER’S FIVE FORCES ANALYSIS
TABLE 24  HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS
5.10.1  DEGREE OF COMPETITION
5.10.2  BARGAINING POWER OF SUPPLIERS
5.10.3  BARGAINING POWER OF BUYERS
5.10.4  THREAT FROM SUBSTITUTES
5.10.5  THREAT FROM NEW ENTRANTS
5.11  KEY CONFERENCES & EVENTS IN 2022
TABLE 25 LIST OF CONFERENCES & EVENTS
5.12  PRICING ANALYSIS
TABLE 26  IMMUNOASSAY: PRICE RANGE FOR IMMUNOASSAY PRODUCTS
5.13  KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1  KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
5.13.2   BUYING CRITERIA
FIGURE 29 KEY BUYING CRITERIA FOR TOP END USERS
TABLE 28 KEY BUYING CRITERIA, BY END USER
5.14  TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.15  SCENARIO-BASED MARKET ASSESSMENT
5.15.1  IMMUNOASSAY MARKET FORECAST
FIGURE 30  PESSIMISTIC SCENARIO
FIGURE 31  OPTIMISTIC SCENARIO
FIGURE 32  REALISTIC SCENARIO

6  IMMUNOASSAY MARKET, BY PRODUCT (Page No. – 113)
6.1  INTRODUCTION
TABLE 29  IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2  REAGENTS & KITS
TABLE 30  IMMUNOASSAY REAGENTS & KITS AVAILABLE IN MARKET
TABLE 31  IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 32  IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2.1  ELISA REAGENTS & KITS
6.2.1.1  WIDE USAGE IN BASIC RESEARCH AND HIGH-THROUGHPUT SCREENING
TABLE 33 ELISA REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.2  RAPID TEST REAGENTS & KITS
6.2.2.1  HIGH DEMAND FOR RAPID TEST REAGENTS & KITS IN REMOTE AREAS TO DRIVE GROWTH
TABLE 34 RAPID TEST REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.3  ELISPOT REAGENTS & KITS
6.2.3.1  HIGH SENSITIVITY, FUNCTIONALITY, AND ADAPTABILITY OF ELISPOT TECHNOLOGY TO DRIVE DEMAND
TABLE 35 ELISPOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.4  WESTERN BLOT REAGENTS & KITS
6.2.4.1  GOLD STANDARD FOR RESULT CONFIRMATION PROMOTES WESTERN BLOTTING REAGENTS & KITS
TABLE 36 WESTERN BLOT REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.2.5   OTHER REAGENTS & KITS
TABLE 37  OTHER IMMUNOASSAY REAGENTS & KITS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3  ANALYZERS
TABLE 38 IMMUNOASSAY ANALYZERS AVAILABLE IN MARKET
TABLE 39 IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.1  IMMUNOASSAY ANALYZERS MARKET, BY TYPE
TABLE 40  IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.3.1.1  OPEN-ENDED SYSTEMS
6.3.1.1.1 FLEXIBILITY AND WIDE AVAILABILITY MAKE OPEN-ENDED SYSTEMS POPULAR AMONG USERS
41 OPEN-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.1.2  CLOSED-ENDED SYSTEMS
6.3.1.2.1  HIGH PRECISION AND AUTOMATION ARE KEY FEATURES OF CLOSED-ENDED SYSTEMS
TABLE 42 CLOSED-ENDED SYSTEMS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.2  IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE
TABLE 43  IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
6.3.2.1  RENTAL PURCHASE
6.3.2.1.1  CONVENIENCE AND LACK OF LIABILITY FOR END USERS DRIVE PREFERENCE FOR DEVICE RENTAL
TABLE 44  RENTAL PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3.2.2  OUTRIGHT PURCHASE
6.3.2.2.1  OUTRIGHT PURCHASE IS FAVORED BY GOVERNMENT ORGANIZATIONS, BIG COMPANIES, AND CROS
TABLE 45 OUTRIGHT PURCHASE IMMUNOASSAY ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)

7  IMMUNOASSAY MARKET, BY TECHNOLOGY (Page No. – 129)
     7.1  INTRODUCTION
TABLE 46 IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
7.2  ELISA
TABLE 47  KEY ELISA SYSTEMS AVAILABLE IN MARKET
TABLE 48  IMMUNOASSAY MARKET FOR ELISA, BY REGION, 2020–2027 (USD MILLION)
7.2.1  ELISA MARKET, BY GENERATION
TABLE 49  IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
7.2.1.1  THIRD-GENERATION & ABOVE
7.2.1.1.1 THIRD- & FOURTH-GEN ELISA SHOW HIGH SPECIFICITY AND ACCURACY
TABLE 50  THIRD-GENERATION & ABOVE ELISA MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.1.2  SECOND-GENERATION & BELOW
7.2.1.2.1  COST-EFFECTIVENESS OF FIRST- AND SECOND-GENERATION TESTS SUPPORTS THEIR USE
TABLE 51  SECOND-GENERATION & BELOW ELISA MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.2  ELISA MARKET, BY TYPE
TABLE 52  IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
7.2.2.1  CLIA
7.2.2.1.1  CLIA HOLDS LARGEST SHARE OF ELISA MARKET, BY TYPE
TABLE 53 CLIA MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.2.2  IFA
7.2.2.2.1  IFA IS USED TO DIAGNOSE ANTIBODIES AGAINST INFECTIOUS PATHOGENS
TABLE 54 IFA MARKET, BY REGION, 2020–2027 (USD MILLION)
7.2.2.3  COLORIMETRIC IMMUNOASSAYS
7.2.2.3.1  INTRODUCTION OF ADVANCED TECHNIQUES WILL SUPPORT MARKET GROWTH
TABLE 55 COLORIMETRIC IMMUNOASSAYS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3  RAPID TESTS
7.3.1  WIDE USE OF RAPID TESTS IN EMERGING COUNTRIES OR AREAS WITH LIMITED TECHNOLOGY ACCESS TO DRIVE GROWTH
TABLE 56  KEY RAPID TESTS AVAILABLE IN MARKET
TABLE 57  IMMUNOASSAY MARKET FOR RAPID TESTS, BY REGION, 2020–2027 (USD MILLION)
7.4  WESTERN BLOTTING
7.4.1  WIDE USE IN RESULT CONFIRMATION AND ANTIBODY DETECTION RESPONSIBLE FOR MARKET GROWTH
TABLE 58  WESTERN BLOTTING SYSTEMS AVAILABLE IN MARKET
TABLE 59  IMMUNOASSAY MARKET FOR WESTERN BLOTTING, BY REGION, 2020–2027 (USD MILLION)
7.5  RADIOIMMUNOASSAYS
7.5.1  HIGH USAGE OF RIA FOR DIAGNOSIS AND DRUG TESTING TO DRIVE GROWTH
TABLE 60  IMMUNOASSAY MARKET FOR RADIOIMMUNOASSAYS, BY REGION, 2020–2027 (USD MILLION)
7.6  ELISPOT
7.6.1  HIGH SENSITIVITY, SPECIFICITY, AND VERSATILITY OF ELISPOT DRIVE ADOPTION OF ASSAYS
TABLE 61  IMMUNOASSAY MARKET FOR ELISPOT, BY REGION, 2020–2027 (USD MILLION)
7.7  OTHER TECHNOLOGIES
TABLE 62  IMMUNOASSAY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)

8  IMMUNOASSAY MARKET, BY SPECIMEN (Page No. – 144)
8.1  INTRODUCTION
TABLE 63  IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
8.2  BLOOD
8.2.1  HIGH RELIABILITY OF BLOOD TESTS WILL ENSURE STABLE MARKET GROWTH
TABLE 64  IMMUNOASSAY MARKET FOR BLOOD SPECIMENS, BY REGION, 2020–2027 (USD MILLION)
8.3  SALIVA
8.3.1  CONVENIENCE AND APPLICATIONS OF SALIVA TESTS TO SUPPORT MARKET GROWTH
TABLE 65 IMMUNOASSAY MARKET FOR SALIVA SPECIMENS, BY REGION, 2020–2027 (USD MILLION)
8.4  URINE
8.4.1  USE IN LAW ENFORCEMENT AND DRUG TESTING APPLICATIONS DRIVES DEMAND FOR URINE-BASED TESTS
TABLE 66 IMMUNOASSAY MARKET FOR URINE SPECIMENS, BY REGION, 2020–2027 (USD MILLION)
8.5  OTHER SPECIMENS
TABLE 67  IMMUNOASSAY MARKET FOR OTHER SPECIMENS, BY REGION, 2020–2027 (USD MILLION)

9  IMMUNOASSAY MARKET, BY APPLICATION (Page No. – 150)
9.1  INTRODUCTION
TABLE 68 IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
9.2  INFECTIOUS DISEASES
9.2.1  RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
TABLE 69 IMMUNOASSAY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
9.3  ENDOCRINOLOGY
9.3.1  RISING GLOBAL DIABETES INCIDENCE WILL DRIVE DEMAND FOR IMMUNOASSAYS
TABLE 70 IMMUNOASSAY MARKET FOR ENDOCRINOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.4  CARDIOLOGY
9.4.1  HIGH BURDEN OF CVD TO SUPPORT MARKET GROWTH
TABLE 71 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR CARDIOLOGY APPLICATIONS
TABLE 72 IMMUNOASSAY MARKET FOR CARDIOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.5  AUTOIMMUNE DISORDERS
9.5.1  RISING ECONOMIC BURDEN OF AUTOIMMUNE DISORDER TREATMENT—A KEY FACTOR DRIVING MARKET GROWTH
TABLE 73 IMMUNOASSAY MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2020–2027 (USD MILLION)
9.6  ALLERGY DIAGNOSTICS
9.6.1  GROWING PREVALENCE OF ALLERGIES TO INCREASE DEMAND FOR IMMUNOASSAYS
TABLE 74 IMMUNOASSAY MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
9.7  ONCOLOGY
9.7.1  RISING BURDEN OF CANCER—A POSITIVE INDICATOR OF MARKET GROWTH
TABLE 75 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 76 IMMUNOASSAY MARKET FOR ONCOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.8  BONE & MINERAL DISORDERS
9.8.1  HIGH DISORDER PREVALENCE INDICATES STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS
TABLE 77 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR BONE & MINERAL DISORDER DIAGNOSIS
TABLE 78 IMMUNOASSAY MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2020–2027 (USD MILLION)
9.9  TOXICOLOGY
9.9.1  DRUG ABUSE AND ILLICIT DRUG CONSUMPTION ENSURE DEMAND FOR IMMUNOASSAYS IN TOXICOLOGY
TABLE 79 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUG MONITORING
TABLE 80 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR DRUGS-OF-ABUSE/TOXICOLOGY ASSAYS
TABLE 81 IMMUNOASSAY MARKET FOR TOXICOLOGY APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.10  BLOOD SCREENING
9.10.1  RISING BLOOD DONATION VOLUMES FAVOR DEMAND FOR IMMUNOASSAYS
TABLE 82 IMMUNOASSAY MARKET FOR BLOOD SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.11 NEWBORN SCREENING
9.11.1  IMMUNOASSAYS USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL—A MAJOR DRIVING FACTOR
TABLE 83 KEY PLAYERS AND IMMUNOASSAY PRODUCTS FOR NEWBORN SCREENING
TABLE 84 IMMUNOASSAY MARKET FOR NEWBORN SCREENING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9.12  OTHER APPLICATIONS
TABLE 85 IMMUNOASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)

10  IMMUNOASSAY MARKET, BY END USER (Page No. – 167)
10.1  INTRODUCTION
TABLE 86 IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2  HOSPITALS & CLINICS
10.2.1  GROWING PATIENT POPULATION AND TESTING VOLUMES DRIVE MARKET GROWTH
TABLE 87 IMMUNOASSAY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
10.3  CLINICAL LABORATORIES
10.3.1  RISING CLINICAL TEST VOLUMES AND REQUIREMENTS SUPPORT USE OF IMMUNOASSAYS IN CLINICAL LABS
TABLE 88 IMMUNOASSAY MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
10.4  PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS
10.4.1  GROWING DRUG DISCOVERY AND CLINICAL STUDY ACTIVITY DRIVES DEMAND FOR IMMUNOASSAYS IN PHARMA-BIOTECH INDUSTRY
TABLE 89 IMMUNOASSAY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2020–2027 (USD MILLION)
10.5  HOME CARE SETTINGS
10.5.1  RELIANCE ON AT-HOME TESTS AND POC DIAGNOSTICS BOOSTS MARKET GROWTH
TABLE 90 IMMUNOASSAY MARKET FOR HOME CARE SETTINGS, BY REGION, 2020–2027 (USD MILLION)
10.6  BLOOD BANKS
10.6.1  RISING DEMAND FOR BLOOD AND GROWING BLOOD DONATION VOLUMES DRIVE USE OF IMMUNOASSAYS FOR SCREENING
TABLE 91 IMMUNOASSAY MARKET FOR BLOOD BANKS, BY REGION, 2020–2027 (USD MILLION)
10.7  RESEARCH & ACADEMIC LABORATORIES
10.7.1  RISING NUMBER OF COLLEGES & UNIVERSITIES DRIVES MARKET GROWTH
TABLE 92 IMMUNOASSAY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)

11  IMMUNOASSAY MARKET, BY REGION (Page No. – 176)
11.1 INTRODUCTION
TABLE 93 IMMUNOASSAY MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 33 NORTH AMERICA: IMMUNOASSAY MARKET SNAPSHOT
TABLE 94 NORTH AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 95 NORTH AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 96 NORTH AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 98 NORTH AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 99 NORTH AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 100 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 101 NORTH AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 102 NORTH AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 103 NORTH AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 104 NORTH AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 US HOLDS LARGEST SHARE IN NORTH AMERICAN MARKET
TABLE 105 US: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 106 US: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 107 US: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 108 US: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 109 US: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 110 US: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 111 US: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 112 US: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 113 US: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 114 US: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.2  CANADA
11.2.2.1  INITIATIVES UNDERTAKEN BY GOVERNMENT BODIES TO SUPPORT GROWTH OF MARKET IN CANADA
TABLE 115 CANADA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 116 CANADA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 118 CANADA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 119 CANADA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 120 CANADA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 121 CANADA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 CANADA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 123 CANADA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 124 CANADA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3  EUROPE
TABLE 125  EUROPE: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 126  EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 127  EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 128  EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 129  EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 130  EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 131  EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 132  EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 133  EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 134  EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 135  EUROPE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1  GERMANY
11.3.1.1  GERMANY HOLDS LARGEST SHARE OF EU IMMUNOASSAY MARKET
TABLE 136 GERMANY: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 137 GERMANY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 138 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 139 GERMANY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 140 GERMANY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 141 GERMANY: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 142 GERMANY: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 143 GERMANY: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 144 GERMANY: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 145 GERMANY: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.2  ITALY
11.3.2.1  GROWING GERIATRIC POPULATION AND INCREASING SUPPORT FOR RESEARCH TO SUPPORT MARKET GROWTH
TABLE 146  ITALY: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 147  ITALY: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 148  ITALY: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 149  ITALY: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 150  ITALY: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 151  ITALY: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 152  ITALY: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 153  ITALY: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 154  ITALY: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 155  ITALY: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.3  FRANCE
11.3.3.1  RISING USE OF POC TESTING AND FAVORABLE REIMBURSEMENT POLICIES MAKE FRANCE A LUCRATIVE MARKET
TABLE 156  FRANCE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 157  FRANCE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 158  FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 159  FRANCE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 160  FRANCE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 161  FRANCE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 162  FRANCE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 163  FRANCE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 164  FRANCE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 165  FRANCE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.4  SPAIN
11.3.4.1  INCREASING ADOPTION OF TECHNOLOGICALLY ADVANCED IMMUNOASSAY SYSTEMS MAKES SPAIN A RELATIVELY LARGE MARKET
TABLE 166  SPAIN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 167  SPAIN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 168  SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 169  SPAIN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 170 SPAIN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 171  SPAIN: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 172  SPAIN: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 173  SPAIN: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 174  SPAIN: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 175  SPAIN: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.5  UK
11.3.5.1  GOVERNMENT SUPPORT FOR DISEASE DIAGNOSTICS AND FAVORABLE INVESTMENT SCENARIO DRIVE MARKET IN UK
TABLE 176  UK: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 177  UK: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 178  UK: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 179  UK: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 180  UK: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 181  UK: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 182  UK: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 183  UK: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 184  UK: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 185  UK: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.6  RUSSIA
11.3.6.1  LACK OF REIMBURSEMENT AND DELAYS IN APPROVAL MAY HINDER MARKET GROWTH
TABLE 186  RUSSIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 187  RUSSIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 188  RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 189  RUSSIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 190  RUSSIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 191  RUSSIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 192  RUSSIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 193  RUSSIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 194  RUSSIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 195  RUSSIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.7  REST OF EUROPE
TABLE 196  REST OF EUROPE: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 197  REST OF EUROPE: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 198  REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 199  REST OF EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 200  REST OF EUROPE: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 201  REST OF EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 202  REST OF EUROPE: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 203  REST OF EUROPE: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 204  REST OF EUROPE: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 205  REST OF EUROPE: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4  ASIA PACIFIC
FIGURE 34  ASIA PACIFIC: IMMUNOASSAY MARKET SNAPSHOT
TABLE 206  ASIA PACIFIC: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 207  ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 208  ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 209  ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 210  ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 211  ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 212  ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 213  ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 214  ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 215  ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 216  ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 JAPAN
11.4.1.1  INVESTMENTS IN HEALTHCARE TECHNOLOGY AND RESEARCH TO SUPPORT GROWTH IN JAPAN
TABLE 217  JAPAN: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 218  JAPAN: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 219  JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 220  JAPAN: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 221  JAPAN: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 222  JAPAN: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 223  JAPAN: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 224  JAPAN: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 225  JAPAN: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 226  JAPAN: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.2  CHINA
11.4.2.1  OPPORTUNITIES FOR GROWTH IN CHINA HAMPERED BY LONG PRODUCT APPROVAL AND REGISTRATION PROCESSES
TABLE 227  CHINA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 228  CHINA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 229  CHINA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 230  CHINA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 231  CHINA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 232  CHINA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 233  CHINA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 234  CHINA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 235  CHINA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 236  CHINA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.3  INDIA
11.4.3.1  GROWING MEDICAL TOURISM AND HEALTHCARE INFRASTRUCTURE WILL DRIVE USE OF IMMUNOASSAYS IN INDIA
TABLE 237  INDIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 238  INDIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 239  INDIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 240  INDIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 241  INDIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 242  INDIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 243  INDIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 244  INDIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 245  INDIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 246  INDIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.4  AUSTRALIA
11.4.4.1  GROWING DISEASE INCIDENCE AND TECHNOLOGICAL DEVELOPMENT DRIVE MARKET GROWTH
TABLE 247  AUSTRALIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 248  AUSTRALIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE  249 AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 250  AUSTRALIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 251  AUSTRALIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 252  AUSTRALIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 253  AUSTRALIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 254  AUSTRALIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 255  AUSTRALIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 256  AUSTRALIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.5  SOUTH KOREA
11.4.5.1  RISING HEALTHCARE SPENDING AND INVESTMENTS IN RESEARCH FUEL MARKET GROWTH
TABLE 257 SOUTH KOREA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 258 SOUTH KOREA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 259 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 260 SOUTH KOREA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 261 SOUTH KOREA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 262 SOUTH KOREA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 263 SOUTH KOREA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 264 SOUTH KOREA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 265 SOUTH KOREA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 266 SOUTH KOREA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.6  INDONESIA
11.4.6.1  INDONESIA HAS BECOME A PROMISING MARKET AND GROWTH HOTSPOT FOR FOREIGN INVESTORS
TABLE 267  INDONESIA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 268  INDONESIA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 269  INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 270  INDONESIA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 271  INDONESIA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 272  INDONESIA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 273  INDONESIA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 274  INDONESIA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 275  INDONESIA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 276 INDONESIA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.7  REST OF ASIA PACIFIC
TABLE 277  REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 278  REST OF ASIA PACIFIC: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 279  REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 280 REST OF ASIA PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 281  REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 282  REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 283  REST OF ASIA PACIFIC: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 284  REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 285  REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 286  REST OF ASIA PACIFIC: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5  LATIN AMERICA
TABLE 287  LATIN AMERICA: IMMUNOASSAY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 288  LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 289  LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 290  LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 291  LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 292  LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 293  LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 294  LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 295  LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 296  LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 297  LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.1  BRAZIL
11.5.1.1  BRAZIL WAS LARGEST MARKET FOR IMMUNOASSAYS IN LATAM
TABLE 298  BRAZIL: IMMUNOASSAY TESTS APPROVED BY ANVISA FOR COVID-19 APPLICATIONS
TABLE 299  BRAZIL: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 300  BRAZIL: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 301  BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 302  BRAZIL: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 303  BRAZIL: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 304  BRAZIL: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 305  BRAZIL: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 306  BRAZIL: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 307  BRAZIL: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 308  BRAZIL: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.2  MEXICO
11.5.2.1  GROWING LAB CONSOLIDATION TO REDUCE NUMBER OF LABS IN MEXICO
TABLE 309  MEXICO: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 310  MEXICO: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 311  MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 312  MEXICO: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 313  MEXICO: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 314  MEXICO: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 315  MEXICO: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 316  MEXICO: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 317  MEXICO: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 318  MEXICO: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5.3  REST OF LATIN AMERICA
TABLE 319  REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 320  REST OF LATIN AMERICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 321  REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 322  REST OF LATIN AMERICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 323  REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 324  REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 325  REST OF LATIN AMERICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 326  REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 327  REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 328  REST OF LATIN AMERICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)
11.6  MIDDLE EAST & AFRICA
11.6.1  LACK OF SKILLED LAB PERSONNEL AND UNFAVORABLE REIMBURSEMENT POLICIES TO LIMIT GROWTH
TABLE 329  MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 330  MIDDLE EAST & AFRICA: IMMUNOASSAY REAGENTS & KITS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 331  MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 332  MIDDLE EAST & AFRICA: IMMUNOASSAY ANALYZERS MARKET, BY PURCHASE MODE, 2020–2027 (USD MILLION)
TABLE 333  MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 334  MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ELISA, BY GENERATION, 2020–2027 (USD MILLION)
TABLE 335  MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET FOR ELISA, BY TYPE, 2020–2027 (USD MILLION)
TABLE 336  MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY SPECIMEN, 2020–2027 (USD MILLION)
TABLE 337  MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 338  MIDDLE EAST & AFRICA: IMMUNOASSAY MARKET, BY END USER, 2020–2027 (USD MILLION)

12  COMPETITIVE LANDSCAPE (Page No. – 321)
12.1  OVERVIEW
12.2  KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1  OVERVIEW OF STRATEGIES ADOPTED BY KEY IMMUNOASSAY PRODUCT MANUFACTURERS
12.3  REVENUE ANALYSIS
FIGURE 35  REVENUE ANALYSIS OF KEY PLAYERS
12.4  MARKET SHARE ANALYSIS
TABLE 339 IMMUNOASSAY MARKET: DEGREE OF COMPETITION
FIGURE 36 MARKET SHARE ANALYSIS, 2021
12.5   COMPANY EVALUATION MATRIX
12.5.1  STARS
12.5.2  EMERGING LEADERS
12.5.3  PERVASIVE PLAYERS
12.5.4  PARTICIPANTS
FIGURE 37 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT
12.6  COMPANY EVALUATION QUADRANT (SMES/START-UPS)
12.6.1  PROGRESSIVE COMPANIES
12.6.2  STARTING BLOCKS
12.6.3  RESPONSIVE COMPANIES
12.6.4  DYNAMIC COMPANIES
FIGURE 38 IMMUNOASSAY MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES
12.7  COMPANY FOOTPRINT ANALYSIS
TABLE 340  COMPANY FOOTPRINT
TABLE 341  COMPANY PRODUCT FOOTPRINT
TABLE 342  COMPANY REGIONAL FOOTPRINT
12.8  COMPETITIVE BENCHMARKING
TABLE 343 IMMUNOASSAY MARKET: DETAILED LIST OF KEY START-UPS/SMES
12.9  COMPETITIVE SCENARIO
12.9.1  PRODUCT LAUNCHES & APPROVALS
TABLE 344 IMMUNOASSAY MARKET: PRODUCT LAUNCHES & APPROVALS, 2019–2022
12.9.2  DEALS
TABLE 345 IMMUNOASSAY MARKET: DEALS, 2019–2022
12.9.3   OTHER DEVELOPMENTS
TABLE 346 IMMUNOASSAY MARKET: OTHER DEVELOPMENTS, 2019–2022

13  COMPANY PROFILES (Page No. – 335)
(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW)*
13.1  MAJOR PLAYERS
13.1.1  ABBOTT LABORATORIES
TABLE 347  ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 39  ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
13.1.2  ROCHE DIAGNOSTICS
TABLE 348  F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
FIGURE 40  F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)
13.1.3  SIEMENS HEALTHINEERS AG
TABLE 349 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 41 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
13.1.4  DANAHER CORPORATION
TABLE 350 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
13.1.5  THERMO FISHER SCIENTIFIC INC.
TABLE 351 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
13.1.6  PERKINELMER, INC.
TABLE 352 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 44 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
13.1.7  BECTON, DICKINSON AND COMPANY
TABLE 353 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 45 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
13.1.8  DIASORIN S.P.A.
TABLE 354 DIASORIN S.P.A.: BUSINESS OVERVIEW
FIGURE 46 DIASORIN S.P.A.: COMPANY SNAPSHOT (2021)
13.1.9  BIO-RAD LABORATORIES, INC.
TABLE 355 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
13.1.10  QUIDEL CORPORATION
TABLE 356 QUIDEL CORPORATION: BUSINESS OVERVIEW
FIGURE 48 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
13.1.11  ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
TABLE 357 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW
FIGURE 49 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2021)
13.1.12  BIOMÉRIEUX
TABLE 358 BIOMÉRIEUX: BUSINESS OVERVIEW
FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2021)
13.1.13  QIAGEN
TABLE 359 QIAGEN: BUSINESS OVERVIEW
FIGURE 51 QIAGEN: COMPANY SNAPSHOT (2021)
13.1.14  SYSMEX CORPORATION
TABLE 360 SYSMEX CORPORATION: BUSINESS OVERVIEW
FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
13.1.15  AGILENT TECHNOLOGIES
TABLE 361 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW
FIGURE 53 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021)
13.1.16  MINDRAY MEDICAL INTERNATIONAL COMPANY
TABLE 362 MINDRAY MEDICAL INTERNATIONAL COMPANY: BUSINESS OVERVIEW
13.2  OTHER PLAYERS
13.2.1  MERCK KGAA
13.2.2  MERIDIAN BIOSCIENCE
13.2.3  BIO-TECHNE
13.2.4  CELLABS
13.2.5  ABNOVA CORPORATION
13.2.6  J. MITRA & CO.
13.2.7  TOSOH CORPORATION (TOSOH BIOSCIENCES)
13.2.8  CELL SCIENCES
13.2.9  ENZO BIOCHEM
13.2.10  CREATIVE DIAGNOSTICS
13.2.11  BOSTER BIOLOGICAL TECHNOLOGY
13.2.12  ELABSCIENCE
13.2.13  WAK-CHEMIE MEDICAL
13.2.14  SERA CARE
13.2.15  EPITOPE DIAGNOSTICS
13.2.16  KAMIYA BIOMEDICAL COMPANY
13.2.17  GYROS PROTEIN TECHNOLOGIES
13.2.18  TRIVITRON HEALTHCARE
13.2.19  INBIOS INTERNATIONAL, INC.

*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

14  APPENDIX (Page No. – 418)
14.1  INSIGHTS FROM INDUSTRY EXPERTS
14.2  DISCUSSION GUIDE
14.3  KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.4  AVAILABLE CUSTOMIZATIONS
14.5  RELATED REPORTS
14.6  AUTHOR DETAILS


    주문/문의폼

    • 리포트 제목은 자동으로 입력됩니다.

    • *항목은 필수항목입니다.

    • 무료샘플은 구입 검토용으로만 의뢰해 주시길 부탁드립니다. 

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com